作者: Nicole Eter , Zoran Hasanbasic , Georgios Keramas , Christine Rech , Helmut Sachs
DOI: 10.1007/S00417-021-05073-8
关键词: Pediatrics 、 Clinical endpoint 、 In patient 、 Population 、 Cohort study 、 Macular degeneration 、 Aflibercept 、 Visual acuity 、 Age related 、 Medicine
摘要: To evaluate the real-world effectiveness of intravitreal aflibercept injections in Germany patients with neovascular age-related macular degeneration over 24 months. PERSEUS was a prospective, non-interventional cohort study. The primary endpoint mean change visual acuity (VA) from baseline. Secondary endpoints included proportion VA gain or loss ≥ 15 letters and frequency examinations. Patients regular (bimonthly after 3 monthly during year 1 and ≥ 4 2) irregular (any other) treatment were analyzed. last observation carried forward (LOCF) observed cases (OC) approach applied for analysis to account missing data. 803 considered effectivity analysis. At month 24, only 38% still under observation. LOCF population 727, OC 279 patients. Treatment-naive improved by 6.3 (LOCF)/8.1 24 months but 3.3 (LOCF)/3.1 treatment. treatment-naive achieving improvement similar between regularly irregularly treated cohorts. However, considerably more cohorts experienced worsening than (LOCF: 18.7% vs. 7.4%). Regular IVT-AFL resulted better outcomes at 24. minority received 2-year period.